



Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo's FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug

November 1, 2017

Site Provides Information and Resources for Consumers as Well as HIV Physicians, Gastroenterologists and Other Healthcare Professionals

SAN FRANCISCO--(BUSINESS WIRE)--Nov. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, announced today that its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), has launched a significantly enhanced version of Mytesi.com, the website for Mytesi® (crofelemer), Napo's first-in-class anti-secretory human prescription drug.

Mytesi® is the first and only anti-diarrheal approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The new Mytesi.com website is designed to provide both people living with HIV or AIDS (PLWHA), and clinicians and other healthcare professionals with information about HIV-related diarrhea and Mytesi®. For PLWHA, the site provides product information in consumer-friendly language, tools to help them facilitate a conversation about HIV-related diarrhea with their physician—including a symptom checklist and a diarrhea symptom questionnaire that can be printed and provided to the doctor—and information about the Mytesi® Copay Savings Card.

A new "Healthcare Professional" area on the site provides Mytesi®-related scientific and clinical trial data for HIV physicians as well as gastroenterologists—many of whom see large numbers of PLWHA.

"As someone living with HIV, the internet is my go-to for anything related to HIV. For newly diagnosed patients, having this information online, presented in a way that is consumable by a non-medical professional, is even more important, as the web is typically the first place one goes to when needing more information. A lot of people feel more comfortable searching on their computer versus talking to a doctor upfront, so it's critical that the right information is out there, available for anyone who's searching for it," stated David Duran, a nationally recognized HIV advocate and writer who contributes to a number of leading HIV-focused publications.

Mytesi® works by normalizing water flow in the intestines, which is different from other anti-diarrheals, and, because Mytesi® is not absorbed into the blood stream, it has few side effects and no drug-drug interactions. Mytesi® is widely available, and people living with HIV/AIDS who are tired of planning their life around diarrhea can ask their provider for a prescription for Mytesi®.

About Mytesi®

Mytesi® (crofelemer) is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal *Croton lechleri* tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

About Napo Pharmaceuticals, Inc.

San Francisco-based Napo Pharmaceuticals, Inc. (Napo), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Napo is a wholly-owned subsidiary of Jaguar Health, Inc., a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis.

For more information about Napo, visit napopharma.com. For more information about Jaguar, please visit jaguar.health.

Jaguar-JAGX

View source version on businesswire.com: <http://www.businesswire.com/news/home/20171101005930/en/>

Source: Jaguar Health, Inc.

KCSA Strategic Communications

Garth Russell, 212-896-1250

grussell@kcsa.com